Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
The company uses iPS cells to develop treatments for diseases relating to the kidney
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
Subscribe To Our Newsletter & Stay Updated
